These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8106091)

  • 21. The neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one affects dopamine-mediated behavior in rodents.
    Khisti RT; Deshpande LS; Chopde CT
    Psychopharmacology (Berl); 2002 May; 161(2):120-8. PubMed ID: 11981591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuropsychopharmacological profile of remoxipride in comparison with clozapine.
    Skuza G; Rogóz Z; Wieczorek A
    Pol J Pharmacol; 1997; 49(1):5-15. PubMed ID: 9431546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 1,3-Di-o-tolylguanidine (DTG) differentially affects acute and tonic formalin pain: antagonism by rimcazole.
    Kest B; Mogil JS; Sternberg WF; Pechnick RN; Liebeskind JC
    Pharmacol Biochem Behav; 1995 Sep; 52(1):175-8. PubMed ID: 7501662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Selective antidopaminergic properties of remoxiprid, a new potential antipsychotic agent].
    Ogren SO; Hall H; Köhler C; Magnusson O; Florvall L
    Arzneimittelforschung; 1985; 35(8):1227-31. PubMed ID: 2866774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
    Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Behavioural effects of chronic treatment with apomorphine in combination with neuroleptic drugs.
    Kenny M; Leonard BE
    J Neurosci Res; 1980; 5(4):291-8. PubMed ID: 6107385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of D1- and D2-dopamine agonists on neocortical and hippocampal EEG activity of rat brain: modulation of rimcazole effect.
    Verma A; Kulkarni SK; Nayar U
    Methods Find Exp Clin Pharmacol; 1993 Oct; 15(8):515-25. PubMed ID: 7905945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Behavioral pharmacologic studies in the monkey with DD-3480.
    Shibuya T; Nishimori T; Matsuda H; Chen PC
    Int J Clin Pharmacol Ther Toxicol; 1982 Jun; 20(6):251-4. PubMed ID: 6125481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of psychotropic drugs on the central dopamine metabolism (example: neuroleptics)].
    Havemann U
    Arzneimittelforschung; 1981; Suppl 27():18-22. PubMed ID: 6118158
    [No Abstract]   [Full Text] [Related]  

  • 30. Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat.
    Lipska BK; Jaskiw GE; Braun AR; Weinberger DR
    Biol Psychiatry; 1995 Aug; 38(4):255-62. PubMed ID: 8547448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Seasonal changes in the behavioral effects of neuroleptics on white rats].
    Otter MIa; Kalda EI; Erik IuP
    Biull Eksp Biol Med; 1986 Nov; 102(11):577-9. PubMed ID: 2877693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amoxapine in experimental psychopharmacology: a neuroleptic or an antidepressant?
    Chermat R; Simon P; Boissier JR
    Arzneimittelforschung; 1979; 29(5):814-20. PubMed ID: 40575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist.
    Bartoszyk GD; Harting J; Minck KO
    J Pharmacol Exp Ther; 1996 Jan; 276(1):41-8. PubMed ID: 8558454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A critical assessment of behavioural test procedures used to analyse dopaminergic and antidopaminergic drugs.
    Nohria V
    Methods Find Exp Clin Pharmacol; 1983; 5(6):357-64. PubMed ID: 6137599
    [No Abstract]   [Full Text] [Related]  

  • 35. Antagonism of the apomorphine-induced yawning by "atypical" neuroleptics.
    Dubuc I; Protais P; Colboc O; Costentin J
    Neuropharmacology; 1982 Nov; 21(11):1203-6. PubMed ID: 6129594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of dextromethorphan on dopamine dependent behaviours in rats.
    Gaikwad RV; Gaonkar RK; Jadhav SA; Thorat VM; Jadhav JH; Balsara JJ
    Indian J Exp Biol; 2007 Aug; 45(8):712-9. PubMed ID: 17877148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Behavioural correlates to the dopamine D-1 and D-2 antagonists.
    Christensen AV; Arnt J; Hyttel J; Svendsen O
    Pol J Pharmacol Pharm; 1984; 36(2-3):249-64. PubMed ID: 6147830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potentiation of cataleptogenic effects of neuroleptics by prostaglandins.
    Herman ZS; Słomińska-Zurek J; Kryk A; Kmieciak-Kołada K
    Pol J Pharmacol Pharm; 1978; 30(5):639-46. PubMed ID: 35782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).
    Megens AA; Awouters FH; Meert TF; Schellekens KH; Niemegeers CJ; Janssen PA
    J Pharmacol Exp Ther; 1992 Jan; 260(1):146-59. PubMed ID: 1370538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BW 234U, (cis-9-[3-(3,5-dimethyl-1-piperazinyl)propyl]carbazole dihydrochloride): a novel antipsychotic agent.
    Ferris RM; Harfenist M; McKenzie GM; Cooper B; Soroko FE; Maxwell RA
    J Pharm Pharmacol; 1982 Jun; 34(6):388-90. PubMed ID: 6124624
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.